David M. Weiner

Dr. Weiner most recently served as the Chief Executive Officer at Amathus Therapeutics. He has over 25 years of experience in the discovery and clinical development of novel therapeutics for neurological and rare diseases. He started his career at ACADIA Pharmaceuticals, where, over a ten-year period, he held a series of discovery research and clinical development roles working on multiple CNS therapeutics, most notably pimavanserin which is approved for the treatment of Parkinson’s disease psychosis. He subsequently joined EMD Serono in a late clinical development role, ultimately leading early clinical development activities in neurology globally. Dr. Weiner has extensive experience in rare disease drug development, serving as Chief Medical Officer and Interim CEO for Proteostasis Therapeutics, and as CMO at aTyr Pharma and Lumos Pharma.

Dr. Weiner received his M.D. from the School of Medicine and Biomedical Sciences, SUNY at Buffalo, and was a Howard Hughes Medical Institute Research Scholar at the NIH in Bethesda. He trained in clinical neurology at New York Hospital, Memorial Sloan Kettering, Cornell Medical Center, and did a post-doctoral fellowship in neuropharmacology at the University of Vermont. Dr. Weiner has authored over 30 scientific publications and multiple patents and serves on multiple clinical and scientific advisory boards, including the Michael J. Fox Foundation for Parkinsons Research.